Results 61 to 70 of about 1,813 (210)

Efficacy of intravenous immunoglobulin (IVIG) affinity-purified anti-desmoglein anti-idiotypic antibodies in the treatment of an experimental model of pemphigus vulgaris

, 2010
Summary Pemphigus vulgaris is a rare life-threatening autoimmune bullous disease caused by immunoglobulin G (IgG) autoantibodies directed against desmogleins 1 and 3. Previously, we showed that intravenous immunoglobulin (IVIG) ameliorates
D Mimouni, M David, Y Shoenfeld, A S Payne, G J Anhalt, C Avivi, M Blank, I Barshack   +7 more
core   +1 more source

Reassessing Remission in Pemphigus Vulgaris: Beyond Complete Remission Towards Meaningful Disease Control

International Journal of Dermatology, EarlyView.
ABSTRACT Current remission criteria for pemphigus vulgaris rely on binary, lesion‐based endpoints that do not capture immunological status, treatment toxicity, or patient quality of life. We argue for a multidimensional framework incorporating minimal disease activity, validated severity scores, glucocorticoid toxicity indices, and patient‐reported ...
Rhea Ahuja, Sumin Hong, Dédée F. Murrell   +2 more
wiley   +1 more source

A case of herpes zoster simulating pemphigus vulgaris flare

Clinical Dermatology Review
Pemphigus vulgaris is an autoimmune bullous disorder caused by autoantibodies directed against desmogleins. There is an increased risk for developing herpes zoster in pemphigus vulgaris due to the prolonged and high doses immunosuppressant therapy. Here,
C Rahul Babu, Pretty Mathew, Bifi Joy, Sridharan Rajiv, P Aparna Praveen   +4 more
doaj   +1 more source

Longitudinal Pathogenic Properties and N-Glycosylation Profile of Antibodies from Patients with Pemphigus after Corticosteroid Treatment

Biomedicines, 2021
Pemphigus vulgaris is an autoimmune disease that occurs due to pathogenic autoantibodies that recognize the following epidermal adhesion proteins: desmogleins.
Marie Petit, Marie-Laure Walet-Balieu, Damien Schapman, Marie-Laure Golinski, Carole Burel, Marion Barray, Laurent Drouot, Maud Maho-Vaillant, Vivien Hébert, Olivier Boyer, Muriel Bardor, Pascal Joly, Sébastien Calbo   +12 more
doaj   +1 more source

Incidence of P200 pemphigoid: A nationwide study

Journal of the European Academy of Dermatology and Venereology, EarlyView.
The anti‐LAMB4 cell‐based immunoassay is a new serological technique that is far superior to dermal immunoblotting for detecting autoantibodies directed against the P200 protein. This method allows a re‐evaluation of the incidence of P200 pemphigoid, which appears to be considerably more frequent than epidermolysis bullosa acquisita.
Fabienne Jouen, Marion Carrette, Marie‐Laure Golinski, Maud Maho‐Vaillant, Alexis Lefebvre, André Gillibert, Pascal Joly, Vivien Hébert   +7 more
wiley   +1 more source

Annular Neutrophilic Variant of Pemphigus Foliaceus

Przegląd Dermatologiczny
Pemphigus belongs to autoimmune blistering disorders involving circulating antibodies against desmogleins, the proteins involved in keratinocyte adhesion.
Vasudha Belgaumkar, Janhvi Shinde, Shekhar Pradhan, Kiran Dange, Neelam Bhatt, Sarthak Varshney   +5 more
doaj   +1 more source

Darier disease—A review highlighting new insights from the Darier Disease International Task Force

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This review provides a global, clinically focused overview of DD, detailing cutaneous and extracutaneous manifestations, disease classification and severity scoring. It emphasizes early recognition, multidisciplinary management and practical guidance for dermatologists to apply evidence‐based care in diverse skin phototypes. Abstract Darier disease (DD)
Sofia Labbouz, Alain Hovnanian, Grace Xiong, Dedee Frances Murrell, Simon M. Mueller, Khaled Ezzedine, Nessa Aghazadeh Mohandesi, Ahmed Salem Aldhaheri, Nissim Asayag, Eulalia Baselga, Chen Nadler, Keith Choate, Chia‐Yu Chu, John Robert Edminister, Emmanuella Guenova, Melis Gönülal, Antoni Gostynski, Ankan Gupta, Lalit Kumar Gupta, Juliette Mazereeuw‐Hautier, Wolfram Hoetzenecker, Peter Itin, Marek Jankowski, Akiharu Kubo, Haur Yueh Lee, Julia Scott Lehman, Anfisa Lepekhova, Márta Medvecz, Jemima E. Mellerio, Verena Moosbrugger‐Martinz, Amy S. Paller, Dóra Plázár, Amadeu José Rodrigues Queiróz, Josep Riera‐Monroig, Ralph Rosa, Matthias Schmuth, Maella Severino Freire, Itzhak Shabat, Jonathan Shapiro, Cory L. Simpson, Diego Soto‐García, Alexander J. Stratigos, Gianluca Abel Tadini, Takuya Takeichi, Kaushal K. Verma, Jakob D. Wikström, Alexander Zink, Michael Ziv, Alexander Navarini, Roni Pircha Dodiuk‐Gad   +49 more
wiley   +1 more source

The Effect of Conventional Immunosuppressive Therapy on Cytokine Serum Levels in Pemphigus Vulgaris Patients

Iranian Journal of Allergy, Asthma and Immunology, 2014
Pemphigus vulgaris is an autoimmune disease, in which the role of Th17 cytokines needs to be further explored. This study was performed to assess serum levels of three interleukins (IL) required for Th17 differentiation (IL-1β, IL-6 and IL-23) and two ...
Hossein Mortazavi, Nafiseh Esmaili, Somayeh Khezri, Ali Khamesipour, Iman Vasheghani Farahani, Maryam Daneshpazhooh, Nima Rezaei   +6 more
doaj  

The Transition from Pemphigus Foliaceus to Pemphigus Vegetans—An Intriguing Phenomenon within the Spectrum of Autoimmune Blistering Diseases: A Case Report

Dermato
Pemphigus vegetans and pemphigus foliaceus are rare autoimmune blistering diseases characterized by the disruption of desmosomal adhesion proteins, particularly desmoglein 3 and desmoglein 1.
Olguța Anca Orzan, Liliana Gabriela Popa, Iulia Badiu, Ana Ion, Călin Giurcăneanu, Beatrice Bălăceanu-Gurău, Irina Tudose   +6 more
doaj   +1 more source

CD4+ T Cells Predict Relapse in Pemphigus Vulgaris Treated With Rituximab: A Retrospective Study

Oral Diseases, EarlyView.
ABSTRACT Objective This study evaluated the CD4+ T‐cell role in mediating post‐Rituximab Pemphigus vulgaris (PV) relapse, comparing CD4+ count and CD4+/CD20+ ratio between patients who achieved remission and those who relapsed. Methods The clinical course of 27 PV patients treated with Rituximab was evaluated after a 32‐month median follow‐up. CD4+ and
Simone Liguori, Noemi Coppola, Elvira Ruoppo, Federica Canfora, Gabriele Mignogna, Ilaria Mormile, Antonia Fiore, Giuseppe Castaldo, Michele Davide Mignogna, Stefania Leuci   +9 more
wiley   +1 more source